---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-020591"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:00:15.862187+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioAffinity stockholders approve reverse stock split, 2024 plan share increase to 1M

## Summary
- Stockholders approved reverse stock split at ratio of 1-for-2 to 1-for-250, at board's discretion.
- Plan amended to increase shares reserved under 2024 Plan from 66,666 to 1,000,000.
- Approved warrant exercise of up to 271,500 shares and anti-dilution adjustments (floor $4.50 for warrants, $3.00 for Series B).
- Six directors elected: Maria Zannes, Steven Girgenti, Peter Knight, Jamie Platt, Roberto Rios, John J. Oppenheimer.
- Ratified WithumSmith+Brown as independent auditor for fiscal year 2026.

## SEC filing metadata
- accession: 0001493152-26-020591
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226020591/0001493152-26-020591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226020591/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-020591
- JSON: https://secwatch.observer/filing/0001493152-26-020591.json
- Plain text: https://secwatch.observer/filing/0001493152-26-020591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.